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ABSTRACT
Objective: To compare mean homeostatic model assessment of insulin resistance (HOMA-IR) in patients
with and without chronic obstructive pulmonary disease (COPD).
Methods: A Case control analytic study was conducted in medical outpatient department of Medial Unit-II
of Dow University of Health Sciences from April 2013 to September 2013. All patients with the diagnosis
of COPD were included as cases. Controls were age match healthy individuals with minor illnesses. Age,
weight, height and forced expiratory volume in one second to forced vital capacity (FEV1/FVC) ratio were
documented. Fasting blood glucose and fasting insulin levels were done. Body mass index (BMI) and IR was
calculated using the formulas. HOMA-IR was compared between cases and controls.
Results: Forty COPD patients were compared with thirty five age match controls. HOMA-IR was found to be
higher in cases as compared to controls (2.85 v/s 2.00) with a p value <0.000.
Conclusion: COPD is one of the chronic debilitating diseases in our region with various extra-pulmonary
complications. We found IR to be present higher in COPD patients compared with healthy controls.
Evaluating the pulmonary function as well as systemic metabolic parameters, may contribute to minimizing
mortality and morbidity.
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INTRODUCTION
Chronic Obstructive Pulmonary Disease is a
systemic disease characterized by the irreversible
airflow obstruction. The airflow restriction is an
abnormal inflammatory response occurring in the
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lungs against harmful particles and gases in the
inhaled air.1 COPD is one of the leading causes
of chronic morbidity and mortality worldwide1
the mortality due to this disease is increasing
rapidly, making it third leading cause of death
by 2020.2 COPD is preventable and treatable.
Once considered primarily a pulmonary disease,
it is now associated with a variety of systemic
manifestations. It is characterized by low grade
chronic inflammatory response in the body which
is associated with several metabolic effects and
systemic complications.3 One of the grave metabolic
associations of any chronic inflammatory activity is
insulin resistance.4,5
Insulin resistance is one of the leading
metabolic and endocrine problems in the world.
It is the mechanism behind and association in
the manifestations of obesity6, dyslipidemias,
cardiovascular6 and cerebrovascular morbidities
and mortalities. In a recent study, it has been

Insulin resistance in COPD versus healthy controls

suggested to be associated with the progression of
vascular endothelial dysfunction in patients with
COPD.7 In one study, IR has been found to be higher
in patients with COPD compared with healthy agematched controls.8 It has been speculated that IR is
a risk factor for the development of atherosclerotic
cardiac disease and even type 2 diabetes mellitus in
the future in patients with COPD.8 Moreover, it is
independent of the severity of airway obstruction
suggesting its early occurrence in the disease
process.3 Thus, insulin resistance carries higher
risk for metabolic and cardiovascular diseases in
patients with COPD even when clinically stable.3
This study compares insulin resistance as mean
HOMA-IR in patients with and without chronic
obstructive pulmonary disease in the region of
Pakistan. There is no study in our region about
the association of IR in COPD patients, which is
a public concern. Therefore, apart from assessing
lung functions in patients with COPD, evaluating
their associated conditions like insulin resistance
will lead to better management and quality of life
in these patients.
METHODS
The study was conducted at Medial Unit-II of
Dow University of Health Sciences from April
2013 to September 2013. All patients who were
attending medical outpatient departmentwith
the diagnosis of COPD for more than one year,
according to the updated American Thoracic
Society/European Respiratory Society (ATS/
ERS) 9 and Global Initiative for Chronic
Obstructive Lung Disease (GOLD)1 guidelines
were considered. Only those subjects were
included in the study which fitted the following
inclusion criteria: A post-bronchodilator forced
expiratory volume in one second (FEV1)/forced
vital capacity (FVC) < or equal to 0.7 confirming
the presence of airflow limitation that is not fully
reversible. They were further classified by the
same criteria into four groups; mild (FEV1%pred
≥80), moderate (FEV1%pred 50-80), severe
(FEV1%pred 30-50) and very severe (FEV1%pred
<30). Patients with following conditions were
excluded from the study: obstructive airways
disease other than COPD (bronchiectasis, cystic
fibrosis or fibrosis due to tuberculosis), smoking
within the last one month, patients on steroids,
known thyroid diseases, hypercortisolism,
diabetes mellitus, hyperlipidemias, ischemic heart
disease, non-pulmonary infective diseases, renal,
cardiac or hepatic failures, autoimmune diseases

and malignancies. Ethical approval was sought
from ethics review committee of the institute
(IRB-370/DUHS-13). A case control analysis was
conducted in the total of forty patients who fitted
in our criteria and were hence enrolled in the
study after performing spirometry and taking
informed consent. Thirty five age-matched healthy
controls attending OPD with minor illnesses like
gastroenteritis and viral flu were enrolled after
taking informed consent.
Data was collected for age, gender, weight and
height and FEV1/FVC ratio. Body Mass Index (BMI)
was calculated and patients allocated to normal,
under or overweight categories accordingly.
Fasting blood samples were obtained by cubital
venipuncture and then transferred to a single
laboratory for analysis. Plasma fasting glucose level
was measured enzymatically using an automated
analyzer. Fasting plasma insulin were measured
by radioimmunoassay. Insulin resistance was
determined for all patients using HOMA-IR, where
HOMA-IR = fasting glucose (mg/dl) x fasting
insulin (mU/L)/ 405.10The pulmonary function
tests of all individuals were performed according to
the criteria recommended by European Respiratory
Society, using a computer-associated spirometer
device (Vmax22D, Sensor Medics, California; USA).
FVC, FEV1 and FEV1/FVC ratio were measured
and absolute values and predicted percent of these
parameters were evaluated. The best three tests
were recorded.11
Statistical Analysis: Data analysis was done
using SPSS version 18.0. Descriptive statistics
were calculated for all continuous variables. Mean
+/- Standard Deviation (SD) was calculated for
age, weight, height, BMI, fasting blood glucose
levels and fasting Insulin levels. Frequencies
& percentages for categorical variables were
calculated. BMI and HOMA-IR with and without
COPD between two groups were compared using
T test. P-value ≤ 0.05 was taken as statistically
significant.
RESULTS
Forty cases of COPD (23 males and 17 females)
and thirty five age match healthy controls (21
males and 14 females) were enrolled in the study.
The age ranged from a minimum of 26 years and
maximum of 60 years with a mean of 40.88 years
± 11.127 years. Body Mass Index was calculated
as weight (in Kg) per height (in meters) squared.
Mean BMI was calculated to be 24.96 Kg/
m2±5.65in cases and 25.19 Kg/m2±5.54in controls
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Table-I: Characteristics of the control group and COPD cases.
Age (years)
Sex
BMI
Disease stage

Cases N=40

Controls N=35

40.88 (SD±11.12)
Male=23, Female=17
24.96 Kg/m2 (SD± 5.65)
Moderate COPD = 30 (75%)
Severe = 10 (25%)

41.9 (SD±11.7)
Male=21, Female=14
25.19 Kg/m2 (SD± 5.54)

with no difference between the two groups (p
value=0.978). However, overall participants were
more overweight in both groups [27 (67.50%) of the
COPD patients and 24 (60%) of the controls].The
characteristics of the two study groups are shown
in Table-I. Patients with COPD were divided
into four groups by the severity of their disease
according to the guidelines.1There were no patients
with mild or very severe severities. Thirty patients
(75%) had moderate COPD and only ten (25%)
were found to be severe. HOMA-IR was calculated
for all patients and found to be higher among cases
as compared to controls (Mean 2.85 v/s 2.00) with
a significant difference noted statistically (60%
v/s 14.28%, p value=0.000).Comparing each BMI
category of total number of patients showed that
BMI status does not affect the presence of insulin
resistance as there are more overweight patients
without insulin resistance (p value=0.038) as
shown in Table-II. Statistical comparison among
independent variables between two groups is
shown in the Table-III. An important observation is
that Fasting glucose levels have shown significant
difference between the two groups (p value=0.011)
which is an independent factor.
Table-II: Comparison of BMI groups
with Insulin resistance.
BMI category

Insulin Resistance
Absent (n)

P value

Present (n)

Underweight
Normal
Overweight

7
12
27

0
5
24

Total

46

29

0.038

-

DISCUSSION
Chronic Obstructive Pulmonary Disease is
recently recognized to have clear extra-pulmonary
effect.12,13 There is a well-known association of
COPD with excess risk of cardiovascular disease
and type 2 diabetes.3 Epidemiological data and
several retrospective studies suggest that diabetes
mellitus is much more common in patients with
COPD than in healthy controls.14,15 Similarly, a
recent observational study has also shown higher
prevalence of metabolic syndrome in patients
with COPD than in healthy subjects (57% v/s
40%).16 In fact, studies have shown that mortality
in patients with COPD is mainly due to nonrespiratory disorders such as cardiovascular
diseases rather than the airway disease itself.17
Systemic inflammation has a clear association
with the presence of metabolic syndrome in COPD
patients.17 This systemic inflammation associated
with COPD is an important concept behind various
metabolic and cardiovascular outcomes in these
patients.3,18
One of the major systemic effects of such a chronic
inflammatory condition is insulin resistance.5
Insulin resistance is a growing pandemic all over
the world. It is an important marker of metabolic
syndrome in general, and is an independent risk
factor for its cardiovascular complications. Systemic
inflammation promotes IR, which in turn contributes
to the development of metabolic syndrome in
people with COPD.3 In developed regions, studies
have also been carried out regarding various
metabolic and inflammatory markers being present
even in stable COPD patient population who

Table-III: Statistical comparison among independent variables between two groups.
Control
Fasting blood glucose (mg/dl)
Fasting insulin level
BMI
HOMA-IR
FEV1/FVC
1508 Pak J Med Sci 2015 Vol. 31 No. 6

Cases (COPD)

Mean (SD)

Mean (SD)

89 (13.70)
9.35 (2.92)
25.2 (5.55)
2.01(0.61)
85.52 (5.53)

98.13 (10.24)
12.04 (4.75)
24.96 (5.65)
2.86 (1.09)
56.67 (10.48)
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P value
0.011
0.978
0.000
-

Insulin resistance in COPD versus healthy controls

have established metabolic syndrome.13A recent
observational multicenter study has measured
various components of metabolic syndrome to be
more frequent in COPD patients with prevalence
of diabetes, osteoporosis, coronary artery disease
and heart failure increasing their morbidity and
mortality.1 Insulin resistance itself is also found to be
present even in stable COPD patients because of the
characteristic low grade inflammation [mean(SD),
3.71(3.63) vs. 1.83(1.17)].8
Comparative
studies
have
demonstrated
increased level of IR in COPD patients with
metabolic syndrome than those without metabolic
syndrome, reflecting prognostic significance in
this subgroup with regards to their cardiovascular
and metabolic outcomes.19,20 This finding however
cannot be independently explained due to the
chronic nature of the disease process and its
underlying chronic inflammation, requiring more
extensive research in this regard, especially in our
population, because future therapies are now being
considered to direct towards targeted inflammatory
markers for appropriate management of this patient
population.18 More recently, a cross sectional study
from the National Health and Nutrition Evaluation
Survey (NHANES) data set (2007–2010) has also
identified many associated factors, including
insulin resistance which has a direct contribution to
the development of metabolic syndrome in patients
with COPD.21Naik et al explicitly explained that
various metabolic factors are linked with COPD.
These factors are contributing the pathogenic
variety needing special attention.22 Therefore, as an
essential part of the spectrum, still a direct effect of
IR on the patients with COPD independent of other
metabolic and inflammatory markers would remain
an area of research as IR is a dynamic connection
between a chronic inflammatory process like COPD
and metabolic derangements.
However, no study has compared an independent
association of IR in patients with COPD regardless
of other metabolic markers with healthy controls. In
a third world country like Pakistan, where COPD
patient population is an important health care
figure on the government and its policies, there is
no study regarding its association with IR or any
other metabolic parameters with its consequent
effects on cardiovascular and endocrine outcomes.
Moreover, studies are required to see the effect of
managing IR as well as various other metabolic
parameters in patients with COPD apart from their
respiratory profiles to improve the morbidity and
mortality.

Our study compares the presence of HOMA-IR
in patients with COPD with healthy age matched
controls. There was no difference in the BMI groups,
with greater frequency of being overweight in both
study populations. Therefore, insulin resistance
was found to have an independent association
with COPD patients regardless of other metabolic
parameters. A recent retrospective observational
analysis of such outpatient population of COPD
has shown higher prevalence of diabetes mellitus
with higher BMI and use of corticosteroids as an
associated factor which might be contributing15,
but our study has excluded such confounding
factor. However, fasting blood sugar and fasting
insulin levels were higher in the COPD patients as
compared to healthy controls. This is an important
independent finding which needs further research
because this has directly affected the calculated
insulin resistance which is higher among COPD
patients (2.85 v/s 2.00, p value <0.000). Whether
this reflects the finding of the general population
is an area of controversial debate, as our sample
size was small, which was a limitation to our study.
The reason being the strict exclusion criteria to take
control on confounders of insulin resistance and a
justification of small size as well.Another important
limitation is that our healthy control population
was not ideal controls, which was due to our ethical
consideration to population sampling.
CONCLUSION
Insulin resistance is found to be higher in patients
with COPD even when stable, compared with
healthy controls in our tertiary setup. In the light of
its well-known contribution to metabolic syndrome
in this chronic disease and its progressive risk to
cause type 2 diabetes and cardiovascular morbidity,
it needs to be evaluated along with other markers in
further studies. Moreover, it may be emphasized to
evaluate COPD patients far beyond their respiratory
condition, during their follow up as this may have
impact on their health care outcomes.
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